Trials / Completed
CompletedNCT00234975
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
Evaluation of Clinical Response and Safety in HIV Positive Subjects Co-infected With Hepatitis C Treated With a Kaletra Containing HAART Regimen
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/Ritonavir | 400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-10-10
- Last updated
- 2013-01-03
Locations
11 sites across 1 country: Puerto Rico
Source: ClinicalTrials.gov record NCT00234975. Inclusion in this directory is not an endorsement.